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Magnetic Resonance Lymphography at 9.4 T Using a
Gadolinium-Based Nanoparticle in Rats
Investigations in Healthy Animals and in a Hindlimb Lymphedema Model
Andreas Müller, PhD,* Peter Fries, MD,* Bijan Jelvani,† François Lux, PhD,‡ Claudia E. Rübe, MD,§
Stephanie Kremp, MSc,§ Pietro Giovanoli, MD,|| Arno Buecker, MD,* Michael D. Menger, MD,†
Matthias W. Laschke, MD, PhD,† and Florian S. Frueh, MD†||
Objectives:Magnetic resonance lymphography (MRL) in small animals is a
promising but challenging tool in preclinical lymphatic research. In this
study, we compared the gadolinium (Gd)-based nanoparticle AGuIX with
Gd-DOTA for interstitial MRL in healthy rats and in a chronic rat hindlimb
lymphedema model.
Materials and Methods: A comparative study with AGuIX and Gd-DOTA for
interstitial MRL was performed in healthy Lewis rats (n = 6). For this purpose,
75 μL of 3 mM AGuIX (containing 30 mM Gd-DOTA side residues) and
75 μL 30 mM Gd-DOTA were injected simultaneously in the right and left
hindlimbs. Repetitive high-resolution, 3-dimensional time-of-flight gradient
recalled echo MRL sequences were acquired over a period of 90 minutes using
a 9.4 T animal scanner. Gadofosveset-enhanced MR angiography and surgical
dissection after methylene blue injection served as supportive imaging tech-
niques. In a subsequent proof-of-principle study, AGuIX-based MRL was inves-
tigated in a hindlimb model of chronic lymphedema (n = 4). Lymphedema of the
right hindlimbs was induced by means of popliteal and inguinal lymphadenec-
tomy and irradiation with 20 Gy. The nonoperated left hindlimbs served as
intraindividual controls. Six, 10, and 14 weeks after lymphadenectomy, MRL in-
vestigations were performed to objectify lymphatic reorganization. Finally, skin
samples of the lymphedematous and the contralateral control hindlimbs were an-
alyzed by means of histology and immunohistochemistry.
Results:AGuIX-based MRL resulted in high-resolution anatomical depiction
of the rodent hindlimb lymphatic system. Signal-to-noise ratio and contrast-
to-noise ratio of the popliteal lymph node were increased directly after injection
and remained significantly elevated for up to 90 minutes after application.
AGuIX provided significantly higher and prolonged signal intensity en-
hancement as compared with Gd-DOTA. Furthermore, AGuIX-based MRL
demonstrated lymphatic regeneration in the histopathologically verified
chronic lymphedema model. Collateral lymphatic vessels were detectable
6 weeks after lymphadenectomy.
Conclusions: This study demonstrates that AGuIX is a suitable contrast agent
for preclinical interstitial MRL in rodents. AGuIX yields anatomical imaging
of lymphatic vessels with diameters greater than 200 μm. Moreover, it resides
in the lymphatic system for a prolonged time. AGuIX may therefore facilitate
high-resolution MRL-based analyses of the lymphatic system in rodents.
Key Words: AGuIX, lymphangiography, lymphatic imaging,
lymph node enhancement, magnetic resonance lymphography,
polysiloxane nanoparticle, small animal lymphography
(Invest Radiol 2017;52: 725–733)
L ymphatic imaging is an emerging field in preclinical research. It hasbeen overshadowed for long by angiogenesis research because
high-resolution imaging techniques were not available for the lym-
phatic vasculature.1 Direct lymphography in small animals is diffi-
cult, and intralymphatic cannulation is not suitable for repetitive in
vivo analyses.2 Hence, interstitial contrast deposition with transport
through lymphatic capillaries represents the logical solution. Several
techniques have been established for interstitial lymphography in
small animals, such as fluorescence microlymphography,3 magnetic
resonance lymphography (MRL),4,5 and near-infrared fluorescence
lymphography.6,7 In contrast to fluorescence-based lymphography, in-
terstitial MRL is not limited by superficial penetration depth and
yields information on tissue quality (ie, fibrosis, fatty deposits). Be-
sides lymphatic vessel imaging, it allows additional lymph node char-
acterization and staging.8
Interstitial MRL in animals has been performed with different
contrast agents. These include gadolinium (Gd)-labeled dendrimers,9,10
macrocyclic Gd-complexes,4,11–13 Gd-labeled dextran,14 and hepa-
tobiliary contrast agents.15 However, the translation of these macro-
molecules into clinical application is restricted by delayed renal
clearance and uptake into the reticulo-endothelial system. Furthermore,
interstitial MRL with commercially available extracellular Gd-chelates
is markedly limited by nonspecific distribution.12 Hence, an ongoing
need exists for contrast agents with better suitability for preclinical
and clinical MRL.
The Gd-based nanoparticle AGuIX has been proposed for
theranostic applications including different imaging modalities
and anatomical localizations.16 The concept of detection and radio-
therapy of malignant brain and lung tumors has been investigated in
laboratory animals.17–19 Intravenously applied AGuIX is currently
under clinical investigation serving as a radiosensitizer for the treat-
ment of brain metastases. Based on previous studies on pharmaco-
dynamic and pharmacokinetic properties, we hypothesized that
AGuIX might be particularly suited for interstitial MRL. For verifi-
cation, we herein performed a comparative study with Gd-DOTA in
healthy rats. Gadofosveset-based MR angiography served as a con-
trol experiment to illustrate the vascular system. In a subsequent
proof-of-principle study, MRL investigations with interstitial AGuIX
application were performed in a chronic lymphedema model of the
rat hindlimb.
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MATERIALS AND METHODS
Contrast Agents
AGuIX has been described previously in detail.16 In brief, it con-
sists of 10 Gd-DOTA species binding to a polysiloxane core. Compared
with other nanoparticles, it has a rather small molecular mass of
8.5 ± 1.0 kDa with a mean hydrodynamic diameter of 3.0 ± 1.0 nm.
The molecule size and the rigid structure yield substantial MR contrast
enhancement with higher r1 relaxivities than for free Gd-DOTA.20 So-
lutions were prepared freshly for each animal from dry substance at a
concentration of 3 mM AGuIX, 145 mM NaCl, 2 mM CaCl2·6 H20,
5 mM HEPES, pH 7.4 from a sterile filtrated stock solution and sterile
pure water (Aqua ad iniectabilia; B. BraunMelsungen AG, Melsungen,
Germany). At a concentration of 3 mM, the nanoparticle solution
contained 30 mM Gd-DOTA side residues.
Gd-DOTA (Dotarem; Guerbet, Aulnay-sous-Bois, France)
served as control contrast agent. Gd-DOTA is clinically approved by
the Food and Drug Administration for intravenous use with MR imag-
ing in the brain (intracranial), spine, and associated tissues in adult and
pediatric patients. Imaging properties of this agent in MRL have previ-
ously been characterized in different animal studies.21,22 The Gd-DOTA
stock solution supplied at 500 mM was diluted to a concentration of
30 mM with sterile pure water. Subsequently, equal doses of Gd were
applied with the corresponding contrast agents for the MR experiment.
For MRL, the fourth phalanx of both hindlimbs was injected in-
tradermally with 75 μL of the contrast medium preparations using a 31-
gauge syringe (Hamilton Bonaduz AG, Bonaduz, Switzerland).
For contrast-enhancedMR angiography, gadofosveset (Vasovist;
Bayer, Leverkusen, Germany) was applied as an intravenous bolus in-
jection at a dose of 0.2 mL/kg, equaling 0.03 mmol/kg body weight,
as described previously.23 Gadofosveset binds reversibly to endogenous
serum albumin, resulting in a longer vascular residence time and a
higher r1 relaxivity with an increase in blood vessel signal intensity (SI).
Animals
All experiments were performed with 3- to 4-month-old male
Lewis rats (Janvier Labs, Le Genest-Saint-Isle, France) exhibiting a
mean bodyweight of 390 ± 40 g. The animalswere housed one per cage
under a 12-hour day/night cycle and were fed ad libitum with water and
standard pellet food (Altromin, Lage, Germany). All experiments
were conducted in accordance with the European legislation on the
protection of animals (Directive 2010/63/EU) and the National Insti-
tutes of Health guidelines on the care and use of laboratory animals
(National Institutes of Health publication #85-23 Rev. 1985) and were
approved by the local governmental animal care committee (permission
number: 67/2015).
Experimental Protocol
In 6 healthy animals, a comparative study with simultaneous in-
tradermal injection of AGulX in the right and Gd-DOTA in the left
hindlimb was conducted. After contrast application, 6 repetitive MRL
scans were performed. After MRL completion, gadofosveset was ap-
plied via a tail vein catheter, and MR angiography studies were
performed. Finally, methylene blue was injected intradermally, the ani-
mals were killed, and the lymphatic system of the hindlimb was dis-
sected under a stereomicroscope for illustration purposes.
In 4 animals, we investigated AGulX for lymphatic imaging in a
chronic lymphedema model. Lymphedema was induced by means of
popliteal and inguinal lymphadenectomy with subsequent irradiation.
Magnetic resonance lymphography investigations were performed 6,
10, and 14 weeks after lymphadenectomy. After the last scan, the ani-
mals were killed and tissue specimens were processed for histological
and immunohistochemical analyses.
Magnetic Resonance Imaging
Animals were examined in a horizontal-bore 9.4 T animal scan-
ner (BioSpec Avance III 94/20; Bruker Biospin GmbH, Ettlingen,
Germany) with a BGA12S gradient system (maximum field strength,
675 mT·m−1; linear inductive rise time, 130 microseconds; maximum
slew rate, 4673 mT/m per second) run with ParaVision 6.0.1 (Bruker
Biospin GmbH). All animals were placed in supine position and trans-
ferred to the magnet tail-first. Imaging was performed using a linearly
polarized coil developed for imaging of the rat abdomen with an inner
diameter of 72mm (Bruker Biospin GmbH). Imaging was performed in
coronal orientation with a 3-dimensional (3D) gradient recalled echo
(GRE) time-of-flight (TOF) sequence adjusted to the blood flow ve-
locity. Because of the low flow velocities experienced perpendicular
to the z axis, this approach led to a reduction of the SI from blood ves-
sels in the hindlimbs. Finally, MR angiography was performed using
a 3D GRE sequence with field of view and matrix settings identical
to MRL. Scan duration was 14 minutes and 36 seconds for MRL
and 15 minutes and 52 seconds for angiography sequences. Details of
the sequence parameters are given in Table 1.
MRL Data Processing and Analysis
Acquired image datawere transferred to an externalworkstation.
Multiplanar reconstruction in coronal, axial, and sagittal orientation,
3D maximum intensity projection, and quantitative analyses of
2-dimensional coronal MR images were performed with the 32-bit
OsiriX v.4.1.2 software (Pixmeo Sarl, Bernex, Switzerland). For the 6
animals of the comparative study, lymph node enhancement after
AGuIX and Gd-DOTA injection was quantified. For determination of
signal-to-noise ratio (SNR), the entire popliteal lymph nodes were seg-
mented manually by regions of interest (ROI). The resulting SIs on
unenhanced and contrast-enhanced images were recorded and averages
per lymph node and time point were calculated thereof. In addition, SI
of the muscle tissue adjacent to the lymph node was assessed on the ba-
sis of ROI measurements. Noise was measured as average standard de-
viation (SD) of the background signal collected from 2 identically sized
ROIs placed independently in the air next to the animals. Signal-to-
noise ratio for each time point investigated was determined as follows:
SNRLNseg ¼ Mean SILN=Mean SDbackground:
From the SI data recorded for the segmented lymph nodes and
adjacent muscle, highest SI values were extracted (SILnmax; SImusclemax),
TABLE 1. Detailed MR Imaging Sequence Parameters
Sequence Purpose TR, ms TE, ms Flip Angle, degree FOV, mm Matrix Voxel Size, μm Zero Fill NA
2D-GRE Localizer 10.0 2.50 10 100  100 150  150 667  667  1000 1  1 1
3D-TOF-GRE Lymphography 10.0 2.50 40 80  70  40 600  528  300 133  133  133 2  2  2 2
3D-GRE Angiography 10.8 2.95 7.5 80  70  40 600  528  300 133  133  133 2  2  2 2
MR indicates magnetic resonance; TR, repetition time; TE, echo time; FOV, field of view; NA, number of averages; 2D, 2-dimensional; GRE, gradient recalled echo;
3D, 3-dimensional; TOF, time-of-flight.
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and maximum SNR for the popliteal lymph nodes and adjacent muscle
of each animal per time point were calculated as:
SNRLNmax ¼ SILNmax=Mean SDbackground:
SNRmusclemax ¼ SImusclemax=Mean SDbackground:
For determination of maximum contrast-to-noise ratio
(CNRLNmax), ROIs were placed in muscle tissue next to the lymph
nodes investigated, and the highest SI within the ROIs were recorded.
Corresponding CNRLNmax was calculated as follows:
CNRLNmax ¼ SILNmax−SImusclemax=Mean SDbackground:
Maximum lymph node–to–muscle ratio (LN/muscle ratio) was
calculated as:
LN=muscle ratio ¼ SNRLNmax=SNRmusclemax:
Lymphedema Animal Model
Chronic lymphedema was established by combined surgical and
radiation ablation of the lymphatic system in right hindlimbs.24 The
nonoperated left hindlimbs served as intraindividual controls.
Surgery
Rats were anesthetized by intraperitoneal injection of keta-
mine (80 mg/kg body weight; Ursotamin; Serumwerk Bernburg
AG, Bernburg, Germany) and xylazine (6 mg/kg body weight; Rompun;
Bayer, Leverkusen, Germany). After depilation of the right hindlimb, the
animals were placed on an operation stage, kept warm with an infrared
lamp, and the right paw was injected intradermally with 0.1 mL methy-
lene blue 10% (Carl Roth GmbH, Karlsruhe, Germany). The collecting
lymphatic vessels of the hindlimb were ligated microsurgically before
piercing the biceps femoris (Fig. 1A), and popliteal (Fig. 1B) as well as
inguinal fat pads were resected. Incisions were closed with 5/0 monofila-
ment (Prolene; Ethicon, Johnson& JohnsonMedical GmbH,Norderstedt,
Germany). Postoperative analgesia was provided with subcutaneous
buprenorphine (0.05 mg/kg body weight; Buprenovet; Bayer Vital
GmbH, Leverkusen, Germany) and tramadol hydrochloride for 3 days
(40mg per 100mL drinkingwater; Tramal; Grünenthal GmbH,Aachen,
Germany). Wound healing and animal behavior were checked regularly.
Irradiation
For planning, a representative rat was scanned with a computed
tomography scanner (Brilliance CT Big Bore; Philips Healthcare,
Eindhoven, the Netherlands). The scan parameters were defined as
120-kV voltage, 450 mA with pixel spacing of 0.10 mm, and slice
thickness of 0.75 mm. This planning data set was used to define the
planning target volume (PTV) in the right groin (Fig. 1C), and the
treatment plan was calculated using the Pinnacle v9.8 planning system
(Philips Healthcare). The PTV was expanded 6 mm and planned with a
single 6-MV photon multileaf collimator field from anterior direction
(Fig. 1D). The dose grid was 1  1  1 mm and the prescribed dose
was 20 Gy in a depth of 25 mm (Fig. 1E). The mean dose in the PTV
was 19.1 ± 1.1 Gy. The animals were irradiated 2 weeks after surgery.
Paw Thickness Measurements
Caliper-measured paw thickness represents a valid surrogate pa-
rameter for rodent hindlimb volumes.25 Repetitive measurements in
isoflurane anesthesia were performed over a period of 14 weeks.
Histology and Immunohistochemistry
Skin samples were fixed in 4% formalin, embedded in paraffin,
and cut into 3-µm thick sections. Individual sections were stained with
hematoxylin and eosin according to standard procedures. Using a BX60
microscope (Olympus, Hamburg, Germany) and the imaging software
cellSens Dimension 1.11 (Olympus), epidermal thickness was assessed.
For blinding purposes, a grid was applied, individual values were eval-
uated in 4 randomized ROIs per section, and average epidermal thick-
ness was calculated. To evaluate the collagen density, additional sections
were stained with Sirius red. Under polarized light, mature collagen fi-
bers (type I) appear reddish due to birefringence.26 The collagen content
was assessed in 6 randomized ROIs per section. Individual thresholding
was used to calculate the Sirius red–positive tissue fraction.
To quantify immune cell infiltration, sections were stainedwith a
polyclonal rabbit antibody against CD68 (1:50; ab125212, Abcam,
Cambridge, United Kingdom) and a polyclonal rabbit antibody against
CD3 (1:100; ab166609, Abcam) followed by a biotinylated goat anti–
rabbit IgG antibody (ready-to-use; Abcam). The biotinylated antibody
was detected by peroxidase-labeled streptavidin (1:50; Sigma-Aldrich,
Taufkirchen, Germany). 3-Amino-9-ethylcarbazole (Abcam) was used
as chromogen. Cell infiltration was quantified in 10 randomized ROIs
per section using the software package ImageJ.27
For immunohistochemical analyses of lymphatic vessels, addi-
tional sections were stained with a polyclonal rabbit antibody against
lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1) (1:600;
ab14917, Abcam). A goat anti–rabbit IgG Alexa555 antibody (1:200;
Life Technologies, Eugene, OR) served as secondary antibody. Cell
FIGURE 1. Animal model. A, Microsurgical ligation of lymphatic vessels.
B, Popliteal lymphadenectomy with lymph node (arrow) and afferent
lymphatic vessels (arrowhead). C, Coronal computed tomography image
for irradiation planning of the right groin (red circle indicates planning
target volume). D, Digitally reconstructed radiograph with multileaf
collimator field used for irradiation. E, Coronal computed tomography
image with isodose lines illustrating the dose distribution. Scale bars:
A = 3.5 mm, B = 6 mm, C = 22 mm, D = 12 mm, E = 19 mm.
Investigative Radiology • Volume 52, Number 12, December 2017 MRL in Rats Using Nanoparticles
© 2017 Wolters Kluwer Health, Inc. All rights reserved. www.investigativeradiology.com 727
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
nuclei were stained with bisbenzimide (1:500; Hoechst 33342, Sigma-
Aldrich) for exact image merging. Quantitative analyses of 6 random-
ized ROIs per section were performed with ImageJ and included the de-
termination of lymphatic vessel density and lymphatic vessel area.
Statistics
Data were analyzed for normal distribution and equal variance.
Two groups were compared using the paired t test (parametric data) or
the Wilcoxon signed rank test (nonparametric data). To test for time ef-
fects within groups, analysis of variance for repeated measurements
(parametric data) or the Friedman test (nonparametric data) were ap-
plied followed by the Dunnett post hoc test. Data are given as
mean ± standard deviation unless otherwise indicated. Dot plots are
shown with the median as single line and the interquartile range
(IQR, 25% to 75% data range) as continuous line. For box plots, the
box includes the IQR and the whiskers illustrate at most 1.5 times the
IQR. The horizontal line represents the median and an open dot repre-
sents the mean. Statistical significance was accepted for P < 0.05.
Statistical analyses were performed with SigmaPlot (Systat Software
Inc, San Jose, CA) and R (R Core Team, Vienna, Austria).28
RESULTS
MRL in Healthy Animals
Lymphangiography
With the selected MR imaging strategies, both lymphatic and
blood vessels of the rat hindlimb could be clearly discriminated
(Fig. 2). Magnetic resonance lymphography performed directly after
AGuIX application allowed high-resolution depiction of the lym-
phatic vessel anatomy in vivo correlating to ex vivo hindlimb dissec-
tion after methylene blue injection (Fig. 2, B, D, and E). The collecting
lymphatic vessels were characterized by a typical appearance with
varying diameter and strong contrast enhancement, whereas veins
appeared smoother and less pronounced (Fig. 2, B and C). Efferent
lymphatic vessels (Fig. 2, B, F, and G) exhibited a tortuous course toward
the inguinal region.
FIGURE 2. MRL andMR angiography in healthy rats. A and B, 3D-TOF-GRE hindlimb scan before (A) and after (B) intradermal AGuIX injection. B, Afferent
lymphatic vessels (arrowhead) draining to the popliteal lymph node (arrow). Double arrowhead indicates efferent lymphatic vessel. C, 3D-GRE
angiography with intravenous gadofosveset ~120 minutes after AGuIX application. D, Anatomical dissection after methylene blue injection. Afferent
lymphatic vessels (arrowhead) piercing the fascia of the biceps femoris (asterisk). Arrow indicates popliteal lymph node. White arrowhead indicates
vascular lymph node pedicle. E, Corresponding dorsolateral view of the paw after AGuIX injection with the collecting lymphatic vessels (arrowhead).
F, MRL with detailed anatomy of the 2 afferent lymphatic vessels (arrowheads), the lymph node (arrow), and the efferent lymphatic vessel (double
arrowhead). G, Additional angiography reveals close vicinity of the short saphenous vein (asterisk). Scale bars: A–D = 8 mm, E = 6.5 mm, F and
G = 1.75 mm.
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Signal intensity of lymphatic vessels decreased over time, but
typical characteristics were preserved (Fig. 3). Afferent and efferent
lymphatic vessels remained delineable up to 60 minutes after AGuIX
injection. In MRL scans performed 75 and 90 minutes after administra-
tion, residual traces of the contrast medium could be detected in the
lymphatic vessels with a substantial amount of AGuIX retained in the
popliteal lymph node as well as at the injection site (Fig. 3, E and F). In
contrast, Gd-DOTA injection resulted in contrasting of veins, afferent
and efferent lymphatic vessels 15 minutes after contrast application
(Fig. 3A). Initial contrast enhancement was stronger for the short
saphenous vein than for the afferent lymphatic vessels. Venous contrast
enhancement was reduced 30 minutes after administration, and
lymphatic vessel imaging was improved at this time point (Fig. 3B).
However, lymphatic vessel delineation was markedly enhanced in
AGuIX-injected hindlimbs, whereas Gd-DOTA was completely cleared
from the injection site after 90 minutes (Fig. 3F).
Lymphadenography
AGuIX and Gd-DOTA injections resulted in an early peak en-
hancement of the popliteal lymph node 15 minutes after injection
(Figs. 3, 4) with a continuous washout throughout the 90-minute obser-
vation period. AGuIX SNRLNseg was significantly higher compared
with Gd-DOTA for all experimental time points (Fig. 4G). AGuIX
injection resulted in a 7.3-fold increase in mean SNRLNseg from
9.5 ± 1.9 to 68.7 ± 14.1. Ninety minutes after administration, mean
SNRLNseg still remained 2.7 times higher than initially recorded. In
contrast, Gd-DOTA injection was associated with a SNRLNseg increase
by a factor of 3.7 from 10.2 ± 2.1 to 37.7 ± 7.4. Furthermore,
mean SNRLNseg in the Gd-DOTA group dropped to baseline already
60 minutes after administration. SNRLNmax measurements revealed
an 11.5-fold increase in the AGuIX group from 19.9 ± 4.0 to
229.0 ± 72.5 (Fig. 4H). Ninety minutes after administration, SNRLNmax
still remained significantly elevated when compared with preinjection
values. For Gd-DOTA injected hindlimbs, SNRLNmax rose 7.0-fold
from 20.3 ± 4.0 to 142.0 ± 48.2 and returned to baseline level as
early as 45 minutes after application.
Accordingly, CNRLNmax in the AGuIX group exhibited a 28.5-fold
increase from 7.6 ± 3.3 before application to 216 ± 68.6 15 minutes after
injection (Fig. 4I). However, 60 minutes after contrast application, no
significant difference to baseline was detectable. Gd-DOTA injection
led to a CNRLNmax increase by a factor of 17.2, from 6.5 ± 1.9 to
117.9 ± 49.9 with return to baseline level 45 minutes after application.
Furthermore, LN/muscle ratio after AGuIX injection showed a
9.7-fold increase from 1.5 ± 0.2 before application to 14.4 ± 4.0
15 minutes after application (Fig. 4J). Injection of Gd-DOTA led to a
6.2-fold increase of LN/muscle ratio from 1.4 ± 0.2 to 8.9 ± 3.3 with
reduction to baseline level 45 minutes after administration.
Characterization of Chronic Hindlimb
Lymphedema in Rats
All incisions healed uneventfully. Combined surgical and radia-
tion ablation of the lymphatic system resulted in increased hindlimb
volumes as indicated by paw thickness measurements (Fig. 5A).
Accordingly, the epidermal layer of the groin skin was significantly
thicker in the lymphedema group (Fig. 5, B–D). Moreover, histological
and immunohistochemical analyses revealed typical hallmarks of
chronic lymphedema, such as tissue fibrosis (Fig. 5, E–G), immune
cell infiltration (Fig. 5, H–K), and increased density and dilatation of
lymphatic vessels (Fig. 5, L–O).
FIGURE 3. 3D-TOF-GREMRLwith AGuIX andGd-DOTA. A, Selective AGuIX uptake into the collecting lymphatic vessels (arrowhead). Gd-DOTA injection
primarily results in contrasting the short saphenous vein (double arrowhead) with minor lymphatic vessel enhancement (white arrowhead). B–F,
Repetitive imaging illustrates quick Gd-DOTA washout from the injection site. Arrow indicates popliteal lymph node. Scale bars: 9.5 mm.
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MRL in Chronic Hindlimb Lymphedema
Six weeks after lymphedema induction, multiple collateral lym-
phatic vessels draining toward the inguinal ligament were detectable, as
illustrated by AGuIX-based MRL (Fig. 6A). These newly visualized
lymphatic vessels exhibited a different morphology with a higher
variation in diameter. Accordingly, lymphatic reorganization on the
dorsum of the paws after 6 weeks was characterized by a dense
reticular network from which the new collateral lymphatic vessels
originated (Fig. 6D). At this time, residual dermal backflow was
present around the ligated lymphatic vessels (Fig. 6, E and F) as compared
with nonoperated control hindlimbs (Fig. 6, G–I). However, subsequent
MRL investigations 10 and 14 weeks after surgery showed a decrease
of collateral lymphatic vessels (Fig. 6, B and C).
DISCUSSION
Magnetic resonance imaging of the lymphatic system exhibits
several advantages. It has higher temporal and spatial resolution than
radionuclide labeling and is suited for detailed 3D investigation of lym-
phatic vessels with a diameter in the submillimeter range. In the clinical
setting, MRL has already been applied for detection of metastases that
have segregated to sentinel lymph nodes,29,30 or for diagnosing lym-
phatic vessel abnormalities.31 However, many MRL methods have
not been translated from preclinical or clinical research to standard pro-
cedures for patients and contrast agents applied for this purpose are not
clinically approved29,30 or used off-label.31
In this study, we evaluated the investigational nanoparticle
AGuIX for MRL in rats. Besides relaxivity (r1 and r2), the size of the
nanoparticles of the contrast agent and its weight and lipophilicity are
the factors that crucially determine pharmacodynamic and pharmacoki-
netic properties in vivo. Accordingly, Kobayashi et al9 demonstrated
that transport with lymphatic vessels, lymph node enhancement, and
elimination from the lymphatic system are correlated to the size of the
contrast agent. Larger particles cause strong and long-lasting contrast
enhancement in lymph nodes, whereas small molecules are eliminated
quickly. The pharmacokinetic properties of AGuIX fit well within these
results. At a molecular weight of 8.5 kDa, AGuIX exhibits slowed tran-
sit through the lymphatic system. In fact, mean SNR of the popliteal
lymph node remained significantly increased up to 90 minutes after
AGuIX injection.
FIGURE 4. Effects of AGuIX andGd-DOTAonpopliteal lymphnode contrast. A–F, Coronal 3D-TOF-GRE scans before (A andD), 15minutes (B and E), and
90 minutes (C and F) after simultaneous application of AGuIX and Gd-DOTA. Scale bars: A–F = 1.5 mm. G–J, Nanoparticle-based MRL (black circles)
results in significantly increased SNRLNseg (G), SNRLNmax (H), CNRLNmax (I), and LN/muscle ratio (J) when compared with Gd-DOTA (white circles).
Measurements are given in arbitrary units. Mean ± standard deviation, n = 6, *P < 0.05 vs Gd-DOTA, #P < 0.05 vs 0 minute.
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Based on its larger hydrodynamic diameter and higher mass as
compared with Gd-DOTA, AGuIX showed a limited transit from the in-
terstitium into venous vessels and was predominantly drained from the
injection site via lymphatic vessels. This effect could be visualized up to
60 minutes after injection. In contrast to the MRL studies performed with
AGuIX, Gd-DOTA application primarily resulted in simultaneous en-
hancement of the short saphenous vein and lymphatic vasculature. Affer-
ent lymphatic vessels were detectable up to 30 minutes after injection
with only minor contrast enhancement. Yet, the effect of early venous
enhancement using contrast agents with extracellular distribution may
significantly impair diagnostic quality of MRL. Our experience with
Gd-DOTA-based MRL is in accordance with results of contrast-
enhanced MRL performed in the clinical setting. Notohamiprodjo
et al32 described concomitant enhancement of veins and lymphatic ves-
sels directly after contrast application in patients with lymphedema.
One limitation of this study consists in the rather long acquisition
time of the high-resolution MRL sequences. Hence, the dynamics of
AGuIX transport through the lymphatic system could not be investi-
gated in detail. However, in comparison with Gd-labeled dendrimers,
a faster transport of AGuIX through lymphatic capillaries and a shorter
half-life in the lymphatic vasculature can be assumed. Analyses in a
comparable setting demonstrated that the uptake of a 4-nm-sized nano-
particle fabricated by incubation of gadofosveset and human serum al-
bumin peaks immediately after injection with subsequent drop-off.33 In
the present study, AGuIX performed better than Gd-DOTAwith respect
to immediate and sustained uptake into the popliteal lymph node. As a
difference to dendrimer-based nanoparticles,9 AGuIX was eliminated
faster from the lymphatic system. The LN/muscle ratio calculation
demonstrated washout from lymph nodes 60 minutes after intradermal
administration. Decrease in SNRLNseg, SNRLNmax, and CNRLNmax was
observed 30 minutes after administration. When compared with
gadofluorine-based MRL contrast agents,12 testing of AGuIX indicated
preferable pharmacokinetics with prolonged signal enhancement in the
lymphatic vessels and lymph nodes.
It has to be emphasized that the herein presented MRL experi-
ments were performed at a magnetic field strength of 9.4 T. High field
strengths facilitate high spatial resolution and are particularly advanta-
geous for small animal MRL. This is reflected by the high quality of
lymphatic vessels depiction presented in this study. However, perform-
ing MRL at high field strengths is ambivalent. At lower field strengths
between 1.5 Tand 3 T, chemical shift- and susceptibility-related artifacts
are less common than at the high field strengths utilized in most animal
scanners. Furthermore, the physical properties of contrast media vary
with the external magnetic field strength applied. For both contrast me-
dia employed in this experimental study, a negative correlation of r1
relaxivity with magnetic field strength has previously been reported.20
Desirable gains in SNR due to the strong magnetic field employed
may therefore be counteracted by impaired contrast media effectivity.
The induction of chronic hindlimb lymphedema in rodents is dif-
ficult and requires invasive lymphatic ablation.34 In the present study,
we combined radical popliteal and inguinal lymphadenectomy with
subsequent irradiation. To mimic the lymphatic damage of clinical
cancer treatment most precisely, we did not leave a skin gap, an oth-
erwise popular experimental procedure in rodents for the prevention
of spontaneous lymphatic reconnection.35,36 Histopathological analyses
14 weeks after surgery revealed typical characteristics of chronic
FIGURE 5. Characterization of chronic hindlimb lymphedema in rats. A, Paw thickness of lymphedematous (red dots) and control (white dots) hindlimbs.
B and C, Hematoxylin and eosin–stained groin skin samples of lymphedematous (B) and control (C) hindlimbs. D, Increased epidermal thickness in the
lymphedema (red box plots) compared with the control group (white box plots). E–G, Sirius red–stained groin sections of lymphedematous (E and G; red
box plots) and control (F andG;white box plots) hindlimbs reveals significant tissue fibrosis. H–K, Paw skin samples of lymphedematous (H) and control
(I) hindlimbs with CD68+ macrophages (black arrowheads). Both macrophages (J) and CD3+ T-lymphocytes (K) are significantly increased in the
lymphedema (red box plots) compared with the control group (white box plots). HPF indicates high-power field. L–O, LYVE-1–stained sections of
lymphedematous (L) and control (M) hindlimbs with higher lymphatic vessel (LV, arrowheads) density and area in the lymphedema (N and O; red box
plots) compared with the control group (white box plots). Nuclei are stained with bisbenzimide (blue): n = 4, *P < 0.05 vs control (white plots). Scale
bars: B and C = 40 μm, E and F = 220 μm, H and I = 60 μm, L and M = 145 μm.
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lymphedema, such as tissue fibrosis, immune cell infiltration, and an
increase in lymphatic vessel density and area. In addition, hindlimb vol-
umes estimated by paw thickness measurements were elevated in the
lymphedema group throughout the 14-week observation period. More-
over, AGuIX-based MRL 6, 10, and 14 weeks after lymphadenectomy
revealed characteristic findings of lymphatic reorganization.
Comparable lymphatic reorganization after popliteal lymphade-
nectomy has been observed in mice using near-infrared fluorescence
imaging.37,38 One week after surgery, rupture of collateral lymphatic
vessels with dermal backflow was reported. After 4 weeks, collateral
pathways toward the inguinal lymph node were established and lym-
phatic vessels showed signs of maturation.37 In our more invasive rat
model, MRL 6 weeks after surgery demonstrated similar collateral
lymph flow. Moreover, we observed residual dermal backflow close
to the ligated lymphatic vessels. The newly visualized lymphatic vessels
exhibited a greater variation in diameter when comparedwith nonoperated
hindlimbs. Importantly, MRL-based analysis of lymphatic vessel matu-
ration remains limited to morphological characterization. In contrast,
near-infrared fluorescence imaging allows dynamic analyses, such as
the assessment of lymphatic vessel contractility.39
Surprisingly, after 10 and 14 weeks, fewer collateral lym-
phatic vessels were detectable. This finding may indicate increased
lymphangiogenesis-independent interstitial fluid drainage.40 However,
it remains unclear towhat extent upstream interruption of the lymphatic
pathway (ie, inguinal lymphadenectomy) or additional irradiation con-
tributed to this phenomenon. Importantly, fibrosis has been shown to be
a strong inhibitor of lymphatic regeneration.41,42 Hence, we speculate
that irradiation-induced tissue fibrosis was the major counterpart of
lymphatic reorganization in the advanced stage of the herein investi-
gated rodent lymphedema model.
Taken together, this study demonstrates that AGuIX-basedMRL
may be ideally suited for preclinical lymphatic imaging in rodents at
high field. It yields sufficiently high spatial and temporal resolution
for anatomical imaging of lymphatic vessels with diameters around
200 μm. Thus, AGuIX-basedMRLmay be a suitable tool to assess lym-
phatic regeneration after reconstructive lymphedema surgery, such as
vascularized lymph node transfer43 or lymphaticovenular anastomo-
sis.44 With shorter scan duration, high-resolution MRL could even be
suitable to analyze lymphatic vessel function or lymphatic drainage,
as already reported by other groups.45 Moreover, AGuIX has been in-
vestigated in mouse models of lung cancer16 and melanoma.46 In both
tumor types, restraint of the contrast agent in induced lesions has been
observed 24 hours after application. This may pave the way for metas-
tasis tracking after intradermal injection.
FIGURE 6. Repetitive AGuIX-based MRL after lymphedema induction. A, Lymphatic reorganization after 6 weeks with collateral lymphatic vessels
(arrows). Lymphatic vessels bridging the defect site (arrowhead) toward the inguinal ligament (not shown). Ten (B) and 14 (C) weeks after
lymphadenectomy, fewer collateral lymphatic vessels (arrows) are detectable. White arrowhead = ligated lymphatic vessels. Dorsolateral view of a
lymphedematous (D) and control (G) hindlimb at week 6. D, Lymphatic network (double arrowhead) on the dorsum of the paw and collateral
lymphatic vessels (arrows). Corresponding coronal sections of the paw (E) and 5 mm proximal of the distal tibiofibular joint (F). Dermal backflow
around the ligated lymphatic vessels on the dorsum of the paw (E, double arrowhead) and less pronounced proximally (F, double arrowhead).
Arrows = collateral lymphatic vessels. G–I, Regular configuration of the lymphatic vessels (arrowheads) in the control hindlimb. Asterisk in F and I = tibia.
Scale bars: A–C = 9.5 mm, D and G = 7.5 mm, E and H = 3 mm, F and I = 5.5 mm.
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